ALX Oncology Holdings UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Okay, thank you. All right. Well, good afternoon, everyone. Thank you for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research here at UBS, and I'm very pleased to have members of the ALX Oncology team with us, including Jason Lettmann, Chief Executive Officer and Chief Medical Officer. Couple of things I would love to start off. Jason, you just reported earnings, not because we about revenue and EPS, but because Not yet.
Soon. talking about That's right.
Talking about the pipeline and the developments and how you're going there. There are two programs we want to talk about today. Obviously, evorpacept, which is at CD47 for breast cancer. We talk about that because there's a major phase II readout that will be coming next year in a multiple indication. Also something that people are not as familiar with, which is ALX2004, which is an EGFR drug conjugate, which is data soon.
Yep. Maybe I could just start with something new, which is this data coming up.
I want you to maybe set the stage for EGFR antibody drug conjugates, something that people are not as familiar with. I would argue that antibody drug conjugates are some of the hottest technologies in oncology right now, so this could be really attractive, but people are still learning about EGFR.
Yeah, sure. Data's coming very, very soon.
Very soon, in December. We just updated that as part of the earnings. First of all, just thank you for having us.
Yeah. We've had a great day here.
It's been a great- Great conference, yep.
I think we're excited about both programs. Both are going to have really important inflection points. We were just talking, our hope this time next year is we're on the doorstep of two registrational studies if we continue to execute, and I think are well on our way. To your point on ALX2004, we have data coming next month. This has been a long time coming for this program, I think, as you followed. We designed, created, built this antibody drug conjugate in-house at ALX. We've been working on this program since 2021. We kept it under wraps for many years, and then started in the clinic about 12, 13 months ago or so.
Okay. This data that's coming will be reporting from our phase I study.
I think as we've discussed with you before, we really have been encouraged by what we've seen on enrollment. We've been encouraged by the way we've been able to escalate in terms of our dose. As I think has been covered, EGFR has been a tough target for an ADC.
Yes. It's expressed in healthy cells, just like in the tumor.
On-target toxicity have been a challenge. The way that we designed ALX2004 was really to address that. We also spent a lot of time optimizing potency.
Specifically, if you go back and look at some of the prior EGFR antibody drug conjugates, I mean, let's be frank, EGFR has been a target that's been around for a long time, monoclonal antibodies, and that's great for binding EGFR and having anti-drug activity by dragging ADC or activities there. By using it as a target to bind cancer cells and bring a payload to it could be very common for hence the excitement of ADCs. But if you're going to hit EGFR in the skin, we're now going to have a lot of rash and brain toxicity and have a rash.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
